A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina
Expert Opinion on Drug Delivery,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 19, 2025
Retinal
diseases
are
a
leading
cause
of
vision
loss,
affecting
millions
people
worldwide.
Current
treatment
options
based
on
invasive
methods
such
as
intravitreal
injections.
Therefore,
there
is
need
for
alternative
therapeutic
strategies
that
both
effective
and
more
patient-friendly.
Topical
drug
delivery
has
gained
attention
preferred
noninvasive
approach,
although
it
hindered
by
several
ocular
barriers.
Cyclodextrin
(CD)-based
nanoparticles
have
emerged
promising
strategy
to
overcome
these
limitations
enhancing
permeability
in
the
posterior
segment
eye.
This
review
discusses
potential
CDs
enabling
pharmaceutical
excipients,
their
role
improving
bioavailability,
provides
examples
CD-based
eye
drop
formulations
currently
under
development
or
undergoing
clinical
trials.
Also,
active
agents
ophthalmology
discussed.
nanoparticle
drops
present
solution
shown
success.
approved
excipients
can
act
ingredients
inherent
retinal
diseases.
Future
innovations
hybrid
systems
integration
novel
compounds
could
provide
efficient
targeted
Язык: Английский
Topical Ocular Drug Delivery: The Impact of Permeation Enhancers
Pharmaceutics,
Год журнала:
2025,
Номер
17(4), С. 447 - 447
Опубликована: Март 31, 2025
Topical
ophthalmic
drug
delivery
targeting
the
posterior
segment
of
eye
has
become
a
key
area
interest
due
to
its
non-invasive
nature,
safety,
ease
application,
patient
compliance,
and
cost-effectiveness.
However,
achievement
effective
bioavailability
in
ocular
is
significant
challenge
unique
barriers,
including
precorneal
factors
anatomical
like
cornea,
conjunctiva,
sclera.
Successful
systems
require
increased
residence
time
improved
corneal
penetration
enhance
intraocular
bioavailability.
A
promising
strategy
overcome
these
barriers
incorporating
enhancers
(DPEs)
into
formulations.
These
compounds
facilitate
by
improving
permeability
across
otherwise
impermeable
or
poorly
permeable
membranes.
At
level,
they
act
through
three
primary
mechanisms:
breaking
tear
film
stability
interfering
with
mucous
layer;
disrupting
membrane
components
such
as
phospholipids
proteins;
loosening
epithelial
cellular
junctions.
DPEs
offer
potential
improve
therapeutic
outcomes,
particularly
for
drugs
eye.
This
review
focused
on
analyzing
current
literature
regarding
use
topical
delivery,
highlighting
their
mechanisms
action
revolutionize
treatments.
Язык: Английский
Areas for improvement in the current care and treatment of dry eye disease
Expert Review of Ophthalmology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 14, 2025
Язык: Английский
Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 28, 2024
Abstract
The
incidence
of
dry
eye
disease
(DED)
has
been
increasing
annually
worldwide,
creating
an
urgent
need
for
new
therapies.
Due
to
the
multifactorial
mechanism
underlying
DED,
traditional
medications
focused
on
decreasing
ocular
surface
inflammation
have
unable
address
all
harmful
factors
and
fail
achieve
a
complete
clinical
cure.
Ferroptosis,
form
programmed
cell
death
characterized
by
lipid
peroxidation,
become
pivotal
contributor
oxidative
stress‐driven
pathology.
Therefore,
therapeutic
targeting
ferroptosis
may
be
attractive
option
management.
Herein,
sialic
acid‐targeting
peptide‐modified
liposome
loaded
with
Cyclosporine
A
(CsA),
typical
anti‐inflammatory
drug,
Ferrostatin‐1
(Fer‐1),
selective
inhibitor,
is
developed
termed
as
CF@SNPs,
combing
sustaining
DED
treatment.
This
multifunctional
liposomal
encapsulation
demonstrates
excellent
aqueous
solubility;
moreover,
peptide
prolongs
retention,
further
enhancing
efficacy.
CF@SNPs
treatment
comprehensively
alleviates
symptoms,
including
improving
corneal
defects,
augmenting
goblet
count,
restoring
tear
secretion.
Specifically,
attenuate
pathology
suppressing
p53‐SLC7A11‐GSH‐dependent
TNF‐α‐associated
inflammatory
cascades,
accompanied
favorable
biocompatibility
in
vivo.
These
results
underscore
promising
potential
this
superior
nano‐formulation
pharmacotherapy.
Язык: Английский